

**MINIMUM PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING
WHERE THERE IS NO PACKAGE LEAFLET, I.e. Combined label and package
leaflet**

2 kg printed bag

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Tylan G50 Premix for medicated feedingstuff

2. COMPOSITION

Each kg contains 50g tylosin activity (as tylosin phosphate)

Granular

3. PACKAGE SIZE

2 kg

4. TARGET SPECIES

Pigs

5. INDICATIONS FOR USE

Indications for use

The prevention and control of enzootic pneumonia.

The treatment and control of *Lawsonia intracellularis*.

The presence of the disease in the group or flock must be established before the product is used.

6. CONTRAINDICATIONS

Contraindications:

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

7. SPECIAL WARNINGS

Special precautions for safe use in the target species:

Use of the product should be in accordance with official, national and regional antimicrobial policies.

For use in pig feed only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Tylosin may induce irritation. Macrolides, such as tylosin, may also cause hypersensitivity (allergy) following injection, inhalation, ingestion or contact with skin or eye.

Hypersensitivity to tylosin may lead to cross reactions to other macrolides and vice versa. Allergic reactions to these substances may occasionally be serious and therefore direct contact should be avoided.

To avoid exposure during preparation of the medicated feed, wear overalls, safety glasses, impervious gloves and wear either a disposable half mask respirator conforming to European Standard EN149 or a non-disposable respirator to European Standard EN140 with a filter to EN143.

Wash hands after use.

In the event of accidental skin contact, wash thoroughly with soap and water. In case of accidental eye contact, flush the eyes with plenty of clean, running water.

Do not handle the product if you are allergic to ingredients in the product.

If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the package leaflet or the label to the physician. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.

Only to be incorporated by a manufacturer who is approved to mix at a rate of below 2 kg per tonne of final feed.

8. ADVERSE REACTIONS

Adverse events

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed on this label, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details on this label, or via your national reporting system.

9. DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION

Mixing Directions:

Prevention and control of enzootic pneumonia:

3-6 mg tylosin activity/kg bodyweight, which may normally be achieved by adding the product at a rate of 2 kg per tonne to give 100 g tylosin base per tonne of feed. Feed as the only ration for 21 days.

Treatment and control of Lawsonia intracellularis:

3-6 mg tylosin activity/kg bodyweight, which may normally be achieved by adding the product at a rate of 2 kg per tonne to give 100 g tylosin base per tonne of feed. Feed as the only ration for 21 days.

The product should be thoroughly mixed into the complete feed. To ensure thorough dispersion of the product it should first be mixed with a suitable quantity of feed ingredients (20-50 kg) before incorporation in the final mix.

The intake of medicated feed depends on the clinical condition of the animals.

In order to obtain the correct dosage, the concentration of the veterinary medicinal product has to be adjusted accordingly.

Incorporation must be in accordance with the veterinary prescription.

10. ADVICE ON CORRECT ADMINISTRATION

11. WITHDRAWAL PERIODS

Withdrawal period:

Meat and offal: Zero Days

12. SPECIAL STORAGE PRECAUTIONS

Store in a dry place.

Do not store above 30° C.

In the finished feed the product will remain stable for 3 months.

13. SPECIAL PRECAUTIONS FOR DISPOSAL

Medicines should not be disposed of via wastewater.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

14. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

15. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 52127/3021

2 kg bag

16. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

17. CONTACT DETAILS

Marketing authorisation holder and contact details to report suspected adverse reactions:

Elanco GmbH
Heinz-Lohmann Strasse 4
D-27472 Cuxhaven
Groden
Germany

Manufacturer responsible for batch release:

Rumenco Limited, Trading as Nettex
Eastern Avenue
Lichfield
Staffordshire
WS13 7SE
United Kingdom

Or

Elanco France S.A.S.
26 rue de la Chapelle, 68330 Huningue,
France

18. OTHER INFORMATION

19. THE WORDS “FOR ANIMAL TREATMENT ONLY”

FOR ANIMAL TREATMENT ONLY.

20. EXPIRY DATE

Exp {month/year}

21. BATCH NUMBER

Lot {number}

22. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the reach and sight of children.

Approved 29 April 2025

Gavin Hall